DOI: 10.32364/2618-8430-2018-1-1-67-70

T.V. Ovsyannikova
RUDN University, Moscow, Russian Federation

Benign breast diseases (BBD) include all kinds of diffuse and focal mastopathy, and diffuse mastopathy is the most common one. The hormone-dependent proliferation is induced mainly by the active metabolites of estrogen. Metabolites of estradiol are its two hydroxy-derivatives: 2-hydroxyestrone (2-ONE1) and 16α-hydroxyestrone (16α-OHE1), their ratio is crucially important for the development of proliferative processes in the mammary glands. The diagnosis of BBD is based on a detailed analysis of the patient’s complaints, features of her history, visual assessment, results of palpation and instrumental examination methods (ultrasound and mammography). Drug therapies for BBD include the drugs with a direct effect on altered breast tissues. Currently, the innovative preparation Indinol^® Forto is actively used. The drug has a wide range of antitumor activity. It shows a mild anti-estrogenic effect and normalizes the hormonal balance, causes selective death of breast cells with abnormally high proliferative activity, suppresses fibrosis and inflammation. The article presents the results of a randomized, double-blind, placebo-controlled multicenter study in which Indinol^® Forto was used in patients with cyclic mastodynia against benign mammary dysplasia.

Key words: benign breast diseases, mastopathy, breast cancer, estrogen, mammary gland, Indinol^® Forto.
For citation: Ovsyannikova T.V. Benign breast diseases — antiprophyliferative therapy. Russian journal of Woman and Child Health. 2018;1(1):–70.